Pharmacological treatments in panic disorder in adults: a network meta-analysis

Giuseppe Guaiana*, Corrado Barbui, Nicholas Meader, Simon J.C. Davies, Toshi A. Furukawa, Hissei Imai, Sofia Dias, Deborah M. Caldwell, Markus Koesters, Aran Tajika, Irene Bighelli, Alessandro Pompoli, Andrea Cipriani

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To compare individual active drugs (antidepressants and benzodiazepines) and placebo in terms of efficacy and acceptability in the acute treatment of panic disorder, with or without agoraphobia. To rank individual active drugs for panic disorder (antidepressants, benzodiazepines and placebo) according to their effectiveness and acceptability. To explore heterogeneity and inconsistency between direct and indirect evidence in the network meta-analyses.

Original languageEnglish
Article numberCD012729
JournalCochrane Database of Systematic Reviews
Issue number10
Publication statusPublished - 28 Oct 2020

Bibliographical note

Funding Information:
We would like to acknowledge the support of the editorial team of the Cochrane Common Mental Disorders (CCMD) Group, and in particular Sarah Dawson, the Information Specialist for the Group, who helped develop the search strategies. The authors and the CCMD Editorial Team are grateful to the following peer reviewers for their time and comments: Karla Duque Jacome, Kerry Dwan, Rafael Freire, Gabriel Kwok, Stella O'Brien and Asta Ratna Prajapati. They would also like to thank Cochrane Copy Edit Support for the team's help. CRG funding acknowledgement: the National Institute for Health Research (NIHR) is the largest single funder of the CCMD Group. Disclaimer: the views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the NIHR, the UK National Health Service or the Department of Health and Social Care.

Funding Information:
GG: is a diplomate of the Academy of Cognitive Therapy. CB: no conflicts of interest. NM: no conflicts of interest. SJD: no conflicts of interest. TAF: has received lecture fees from Eli Lilly, Meiji, Mochida, MSD, Otsuka, Pfizer, Shionogi and Mitsubishi-Tanabe, and consultancy fees from Sekisui Chemicals and Takeda Science Foundation. He has received royalties from Igaku-Shoin, Seiwa-Shoten and Nihon Bunka Kagaku-sha publishers. He has received grant or research support from the Japanese Ministry of Education, Science, and Technology, the Japanese Ministry of Health, Labor and Welfare, the Japan Foundation for Neuroscience and Mental Health, Mitsubishi-Tanabe and Mochida. He is diplomate of the Academy of Cognitive Therapy. TAF has a patent 2018-177688 pending. HI: no conflicts of interest. SD: no conflicts of interest. DC: no conflicts of interest.

Publisher Copyright:
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cite this